Zeo ScientifiX, Inc.

ZEOX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-5.5M $-4.7M $-7.0M $-8.9M $-12.8M $-12.6M $-1.7M $-3.5M
Depreciation & Amortization $73.0K $74.0K $486.0K $332.5K $52.7K
Depreciation $73.0K $74.0K $106.0K $82.0K $52.7K $36.8K $14.8K $7.8K
Amortization
Stock-Based Compensation $4.7M $3.9M $3.2M $3.9M $8.7M $9.9M $727.4K $4.0M
Net Cash from Operating Activities $-718.0K $-1.5M $-2.2M $-3.2M $-2.7M $-1.8M $-565.5K $-512.0K
Investing Activities
Capital Expenditures $23.0K $26.0K $824.7K $424.7K $138.7K $32.7K $4.6K
Business Acquisitions
Net Cash from Investing Activities $-23.0K $-45.0K $615.0K $-824.7K $-424.7K $-138.7K $-32.7K $95.5K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $305.0K $396.0K $-415.0K $7.6M $2.6M $2.4M $687.7K $420.0K
Net Change in Cash $458.2K $89.5K
Free Cash Flow $-741.0K $-2.2M $-4.0M $-3.1M $-2.0M $-598.2K $-516.6K
← Newer Page 1 of 2 Older →